Amarin Corporation plc (ADR)


Stock Update (NASDAQ:AMRN): Amarin Corporation plc (ADR) Shines Light on CHERRY study

Amarin Corporation plc (ADR) (NASDAQ:AMRN) commented on new data from the CHERRY study that supports the hypothesis under investigation in Amarin’s cardiovascular outcomes study …

Stock Update (NASDAQ:AMRN): Amarin Corporation plc (ADR) Announces Encore Presentation at the European Society of Cardiology (ESC) 2015 Annual Congress

Amarin Corporation plc (ADR) (NASDAQ:AMRN) announced the encore presentation of findings from a post-hoc analysis examining the effects of icosapent ethyl (Vascepa®) on Apolipoprotein …

Stock Update (NASDAQ:AMRN): Amarin Corporation plc (ADR) Promotes Joseph T. Kennedy to Executive Vice President, General Counsel and Strategic Initiatives

Amarin Corporation plc (ADR) (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today the promotion …

Oppenheimer Weighs in on Amarin Corporation plc (ADR) Following 2Q:15 Results

Oppenheimer analyst Akiva Felt weighed in with a few insights on Amarin Corporation plc (ADR)(NASDAQ:AMRN), after the pharmaceutical company released its second-quarter results last week. …

Company Update (NASDAQ:AMRN): First Amendment Decision a Win for Amarin Corporation plc (ADR) and Physician Plaintiffs

Amarin Corporation plc (ADR) (NASDAQ:AMRN) announced a United States District Court has ruled that Amarin may promote to healthcare professionals certain uses of Amarin’slead …

Stock Update (NASDAQ:AMRN): Amarin Corporation plc (ADR) Reports 2Q15 Financial Results and Provides Update on Operations

Amarin Corporation plc (ADR) (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced financial results …

Amarin Corporation (AMRN) Announces Upcoming Presentations of Two Eicosapentaenoic Acid (EPA) Studies at the APC

Amarin Corporation plc (ADR) (NASDAQ:AMRN) announced the presentation of findings from two studies, a retrospective study in which patients were switched from an EPA …

Company Update (NASDAQ:AMRN): Amarin Corporation plc (ADR) Granted Summary Judgment Motion in Suit Against FDA Seeking New Chemical Entity Market Exclusivity for Vascepa® Capsules

Amarin Corporation plc (ADR) (NASDAQ:AMRN), announced today that Judge Randolph D. Moss of the federal district court for the District of Columbia has granted …

Oppenheimer Maintains Cautious Stance On Amarin Following 4Q14 Results

Oppenheimer analyst Akiva Felt came out with his views on Amarin Corporation plc (ADR) (NASDAQ:AMRN), after the company reported its fourth-quarter financial results. The company reported quarterly …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts